Provided by Tiger Trade Technology Pte. Ltd.

Corcept Therapeutics

35.23
-0.4710-1.32%
Volume:246.81K
Turnover:8.64M
Market Cap:3.75B
PE:42.96
High:35.43
Open:34.56
Low:34.35
Close:35.70
52wk High:117.33
52wk Low:28.66
Shares:106.37M
Float Shares:86.88M
Volume Ratio:0.28
T/O Rate:0.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.8200
EPS(LYR):0.8200
ROE:15.01%
ROA:3.34%
PB:5.78
PE(LYR):42.96

Loading ...

Corcept Therapeutics Shares Down 16% After FDA Rejection Letter Reveals Repeated Warnings

THOMSON REUTERS
·
Jan 30

BUZZ-U.S. STOCKS ON THE MOVE-ResMed, Stryker, ALX Oncology

Reuters
·
Jan 30

BUZZ-Corcept tumbles after FDA rejection letter reveals repeated warnings

Reuters
·
Jan 30

Top Growth Companies With High Insider Ownership In January 2026

Simply Wall St.
·
Jan 26

Corcept Therapeutics put volume heavy and directionally bearish

TIPRANKS
·
Jan 23

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Corcept Therapeutics (CORT), Intuitive Surgical (ISRG) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Jan 23

Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 23

Corcept Therapeutics (CORT.US) Announces Positive Key Phase 3 Cancer Drug Results, Potential Launch Next Year

Stock News
·
Jan 23

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, JPMorgan, Intel

Reuters
·
Jan 23

Corcept Therapeutics price target raised to $105 from $90 at H.C. Wainwright

TIPRANKS
·
Jan 23

Corcept Therapeutics rises 17.7%

TIPRANKS
·
Jan 22

BUZZ-U.S. STOCKS ON THE MOVE- Medicus Pharma, Lam Research, Applied Digital

Reuters
·
Jan 22

Corcept Therapeutics Phase 3 ROSELLA Trial Achieves Survival Benefit

TIPRANKS
·
Jan 22

BUZZ-Corcept rises after ovarian cancer drug cuts risk of death in late-stage trial

Reuters
·
Jan 22

Corcept Therapeutics Shares up 34.82% Premarket After Experimental Ovarian Cancer Drug Meets Main Goal in Late-Stage Trial

THOMSON REUTERS
·
Jan 22

Corcept Therapeutics reports ROSELLA trial meets primary endpoint

TIPRANKS
·
Jan 22

Corcept Therapeutics Reports Phase 3 ROSELLA Trial Success for Relacorilant in Platinum-Resistant Ovarian Cancer

Reuters
·
Jan 22

Corcept Therapeutics Inc - Phase 3 Rosella Trial Meets Overall Survival Endpoint

THOMSON REUTERS
·
Jan 22

Corcept Therapeutics Inc - Data Show 35% Reduction in Risk of Death

THOMSON REUTERS
·
Jan 22

Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer

THOMSON REUTERS
·
Jan 22